Short Interest in Ipsen S.A. (OTCMKTS:IPSEY) Expands By 107.1%

Ipsen S.A. (OTCMKTS:IPSEY) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,900 shares, an increase of 107.1% from the December 31st total of 1,400 shares. Based on an average daily volume of 2,300 shares, the days-to-cover ratio is presently 1.3 days.

Ipsen Stock Up 1.5 %

Shares of OTCMKTS:IPSEY traded up $0.48 on Wednesday, hitting $31.56. 426 shares of the company’s stock were exchanged, compared to its average volume of 693. Ipsen has a 12 month low of $27.00 and a 12 month high of $34.06. The business’s 50 day simple moving average is $29.39 and its two-hundred day simple moving average is $29.76.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.